Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schatz, Desmond A
DESIGNATE, NCT05574335: Siplizumab in T1DM	Active, not recruiting	1/2	120	US	Siplizumab, TCD 601	National Institute of Allergy and Infectious Diseases (NIAID)	Type 1 Diabetes Mellitus	12/26	12/27
Philipson, Louis
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function	Active, not recruiting	2	140	Europe, US, RoW	Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo	Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.	Recent Onset type1 Diabetes	04/24	04/26
DESIGNATE, NCT05574335: Siplizumab in T1DM	Active, not recruiting	1/2	120	US	Siplizumab, TCD 601	National Institute of Allergy and Infectious Diseases (NIAID)	Type 1 Diabetes Mellitus	12/26	12/27
Reyes, Demetra
DESIGNATE, NCT05574335: Siplizumab in T1DM	Active, not recruiting	1/2	120	US	Siplizumab, TCD 601	National Institute of Allergy and Infectious Diseases (NIAID)	Type 1 Diabetes Mellitus	12/26	12/27